MJardin Group, Inc. (“MJardin” or the “Company”) (CSE:MJAR), a leader in cannabis management, today announced that its WILL cultivation facility in Brampton, Ontario has received its first license to sell cannabis under the Cannabis Act (Canada), which went into effect on October 17, 2018.

The license allows MJardin to supply and sell finished cannabis products to provincial governments throughout Canada and through Canada’s distribution and retail supply chain. The 32,800 square foot facility has a current production capacity of 3,000 kg per year and MJardin has plans to expand WILL’s existing facility and increase total production capacity to over 5,000 kg per year.

“Our first sales license in Canada is a key development for MJardin and a testament to the experience of our team and our ability to efficiently execute our business strategy in the markets we enter,” said Rishi Gautam, Chairman and Chief Executive Officer of MJardin. “The Canadian cannabis market is facing severe supply shortages due to strong consumer demand throughout the country. This license will accelerate MJardin’s sales in Canada and allow us to deliver significant supply to the market to meet growing demand for high quality medicinal and adult-use cannabis products.”

Earlier this month, MJardin announced that its cultivation and extraction facility in Lower Sackville, Nova Scotia owned by AtlantiCann Medical Inc., in which MJardin has a 50% equity interest, was granted a license by Health Canada for cannabis cultivation. The new state-of-the-art, 48,000 square foot cultivation and extraction facility has a production capacity of 6,000 kg per year, with expansion planned for an additional 20,000 square feet by the end of 2019.